Unknown

Dataset Information

0

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.


ABSTRACT: Single nucleotide polymorphisms (SNPs) in FC?-receptor genes FCGR3A (rs396991) and FCGR2A (rs1801274) influence the affinity of the Fc portion of anti-CD20 immunoglobulin G1 monoclonal antibody. Their roles in diffuse large B-cell lymphoma (DLBCL) treated with rituximab in combination with anthracycline-based chemotherapy remain controversial. To address this question, we genotyped FCGR2A and FCGR3A SNPs in two prospective DLBCL cohorts from Lymphoma Study Association trials (N?=?554) and Iowa/Mayo Specialized Program Of Research Excellence (N?=?580). Correlations with treatment response and hematological toxicity were assessed in Lymphoma Study Association. Correlation with event-free survival (EFS) and overall survival (OS) was performed in both cohorts, followed by a meta-analysis to increase power. Our study shows the absence of correlation between these SNPs and treatment response. Grades 3 and 4 febrile neutropenia during treatment was more frequently observed in FCGR3A VV (39%) than VF (29%) and FF (32%) carriers (p?=?0.04). Our analysis for EFS and OS shows that FCGR3A was not associated with outcome. In a meta-analysis using an ordinal model, FCGR2A (per R allele) was associated with a better EFS (hazard ratio?=?0.87; 95%CI, 0.76-0.99; p?=?0.04) and OS (hazard ratio?=?0.86; 95%CI, 0.73-1.00; p?=?0.05) which was not altered after adjustment for the International Prognostic Index. Overall, our data demonstrate that patients with DLBCL with the low-affinity FC?RIIA RR had an unexpectedly better outcome than FC?RIIA H carriers. Whether rituximab efficacy is improved in FC?RIIA RR patients due a clearance reduction or other functions of FC?RIIA in DLBCL should be investigated (clinicaltrials.gov identifiers: NCT00135499, NTC00135499 NCT00140595, NCT00144807, NCT00144755, NCT01087424, and NCT00301821). Copyright © 2016 John Wiley & Sons, Ltd.

SUBMITTER: Ghesquieres H 

PROVIDER: S-EPMC5716925 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Single nucleotide polymorphisms (SNPs) in FCγ-receptor genes FCGR3A (rs396991) and FCGR2A (rs1801274) influence the affinity of the Fc portion of anti-CD20 immunoglobulin G1 monoclonal antibody. Their roles in diffuse large B-cell lymphoma (DLBCL) treated with rituximab in combination with anthracycline-based chemotherapy remain controversial. To address this question, we genotyped FCGR2A and FCGR3A SNPs in two prospective DLBCL cohorts from Lymphoma Study Association trials (N = 554) and Iowa/M  ...[more]

Similar Datasets

| S-EPMC9422037 | biostudies-literature
| S-EPMC4558593 | biostudies-literature
| S-EPMC4879713 | biostudies-literature
| S-EPMC3965261 | biostudies-literature
| S-EPMC10999948 | biostudies-literature
| S-EPMC4144364 | biostudies-literature
| S-EPMC7230391 | biostudies-literature
| S-EPMC10071786 | biostudies-literature
2015-05-15 | GSE68895 | GEO
| S-EPMC10687412 | biostudies-literature